SCHEMBL2408295

SCHEMBL2408295

Clc1ncc2cccnc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NR4A2 P43354 1/20 0.39
CCR1 P32246 2/20 0.39
CCR8 P51685 2/20 0.39
GMNN O75496 1/20 0.39
TP53 P04637 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MMP2 P08253 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
MMP9 P14780 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5794086 0.74 PSMD14 (0.42) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL29536760 0.74 NUDT1 (0.42) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL22479754 0.74 ALDH1A1 (0.41) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL4143004 0.74 ALDH1A1 (0.41) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL3001006 0.74 KDM4E (0.44) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL29808133 0.74 ALDH1A1 (0.41) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL5489083 0.74 NUDT1 (0.42) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL27982720 0.73 CCR1 (0.52) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL29671296 0.71 ALDH1A1 (0.52) RPS6KA5ALDH1A1KDM4ELMNAMEN1
SCHEMBL169736 0.71 ALDH1A1 (0.52) RPS6KA5ALDH1A1KDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070082920-A1 NAD+-dependent DNA ligase inhibitors Ricerca Biosciences, LLC 2007-04-12 US claimed
WO-2025067457-A1 HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-04-03 WO disclosed
WO-2024125464-A1 TETRAHYDROISOQUINOLIN-ONE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-20 WO disclosed
US-20240182470-A1 KRASG12C MUTANT PROTEIN INHIBITOR, PREARATION AND USE THEREOF YA THERAPEUTICS INC (CN) 2024-06-06 US disclosed
EP-3630759-B1 COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-05-01 EP disclosed
CN-115160309-B KRAS G12C Preparation and application of mutant protein heterocyclic inhibitor 药雅科技(上海)有限公司 2024-04-09 CN disclosed
US-11932638-B2 Ion channel inhibitor compounds for cancer treatment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) 2024-03-19 US disclosed
CN-115160309-A KRAS G12C Preparation and application of mutant protein heterocyclic inhibitor 药雅科技(上海)有限公司 2022-10-11 CN disclosed
WO-2022193871-A1 PREPARATION AND USE OF KRASG12D MUTANT PROTEIN INHIBITOR 药雅科技(上海)有限公司 2022-09-22 WO disclosed
WO-2022193982-A1 PREPARATION AND USE OF KRASG12C MUTEIN INHIBITOR 药雅科技(上海)有限公司 2022-09-22 WO disclosed
US-20120316184-A1 NOVEL MICROBICIDES SYNGENTA CROP PROTECTION LLC (US) 2012-12-13 US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
WO-2011104183-A1 NOVEL MICROBICIDES SYNGENTA PARTICIPATIONS AG (CH) 2011-09-01 WO disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
WO-2010084438-A1 AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS PFIZER INC. (US) 2010-07-29 WO disclosed
US-20070082920-A1 NAD+-dependent DNA ligase inhibitors Ricerca Biosciences, LLC 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182470-A1 KRASG12C MUTANT PROTEIN INHIBITOR, PREARATION AND USE THEREOF KRAS, NRAS, HRAS RPS6KA5 694/4885ALDH1A1 3780/4885KDM4E 3623/4885
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A RPS6KA5 2468/4885ALDH1A1 585/4885KDM4E 1344/4885
US-11932638-B2 Ion channel inhibitor compounds for cancer treatment CACNA1E, KCNA1, KCNT1 RPS6KA5 580/4885ALDH1A1 680/4885KDM4E 3118/4885
US-20070082920-A1 NAD+-dependent DNA ligase inhibitors LIG3, LIG1, NQO1 RPS6KA5 2520/4885ALDH1A1 361/4885KDM4E 1694/4885
US-20120316184-A1 NOVEL MICROBICIDES NOX1, MSR1, FPR1 RPS6KA5 3760/4885ALDH1A1 116/4885KDM4E 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.